Roisin Connolly

Assistant Professor

20022018
If you made any changes in Pure these will be visible here soon.

Fingerprint Fingerprint is based on mining the text of the experts' scientific documents to create an index of weighted terms, which defines the key subjects of each individual researcher.

  • 8 Similar Profiles
Breast Neoplasms Medicine & Life Sciences
Therapeutics Medicine & Life Sciences
Neoplasms Medicine & Life Sciences
Drug Therapy Medicine & Life Sciences
Aromatase Inhibitors Medicine & Life Sciences
Epigenomics Medicine & Life Sciences
Tamoxifen Medicine & Life Sciences
Triple Negative Breast Neoplasms Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 2002 2018

A phase II study evaluating the efficacy of zoledronic acid in prevention of aromatase inhibitor-associated musculoskeletal symptoms: the ZAP trial

Santa-Maria, C. A., Bardia, A., Blackford, A. L., Snyder, C., Connolly, R. M., Fetting, J. H., Hayes, D. F., Jeter, S. C., Miller, R. S., Nguyen, A., Quinlan, K., Rosner, G. L., Slater, S., Storniolo, A. M., Wolff, A. C., Zorzi, J., Henry, N. L. & Stearns, V., May 11 2018, (Accepted/In press) In : Breast Cancer Research and Treatment. p. 1-9 9 p.

Research output: Contribution to journalArticle

zoledronic acid
letrozole
Aromatase Inhibitors
exemestane
Pharmacogenetics

E2112: Randomized phase III trial of endocrine therapy plus entinostat/placebo in patients with hormone receptor-positive advanced breast cancer

Yeruva, S. L. H., Zhao, F., Miller, K. D., Tevaarwerk, A. J., Wagner, L. I., Gray, R. J., Sparano, J. A. & Connolly, R. M., Dec 1 2018, In : npj Breast Cancer. 4, 1, 4

Research output: Contribution to journalReview article

exemestane
Placebos
Hormones
Breast Neoplasms
Aromatase Inhibitors

Phase I study combining the aurora kinase a inhibitor alisertib with mFOLFOX in gastrointestinal cancer

Goff, L. W., Azad, N., Stein, S., Whisenant, J. G., Koyama, T., Vaishampayan, U., Hochster, H., Connolly, R., Weise, A., LoRusso, P. M., Salaria, S. N., El-Rifai, W. & Berlin, J. D., Jan 1 2018, (Accepted/In press) In : Investigational New Drugs.

Research output: Contribution to journalArticle

Aurora Kinases
Gastrointestinal Neoplasms
Aurora Kinase A
oxaliplatin
Maximum Tolerated Dose

Racial disparities in the rate of cardiotoxicity of HER2-targeted therapies among women with early breast cancer

Litvak, A., Batukbhai, B., Russell, S. D., Tsai, H. L., Rosner, G. L., Jeter, S. C., Armstrong, D., Emens, L. A., Fetting, J., Wolff, A. C., Silhy, R., Stearns, V. & Connolly, R. M., Jan 1 2018, (Accepted/In press) In : Cancer.

Research output: Contribution to journalArticle

Breast Neoplasms
Therapeutics
Confidence Intervals
Stroke Volume
Incidence

Combination epigenetic therapy in advanced breast cancer with 5-azacitidine and entinostat: A phase II national cancer institute/stand up to cancer study

Connolly, R. M. , Li, H. , Jankowitz, R. C. , Zhang, Z. , Rudek, M. A. , Jeter, S. C. , Slater, S. A. , Powers, P. , Wolff, A. C. , Fetting, J. H. , Brufsky, A. , Piekarz, R. , Ahuja, N. , Laird, P. W. , Shen, H. , Weisenberger, D. J. , Cope, L. , Herman, J. G. , Somlo, G. , Garcia, A. A. & 5 others Jones, P. A., Baylin, S. B., Davidson, N. E., Zahnow, C. A. & Stearns, V., Jun 1 2017, In : Clinical Cancer Research. 23, 11, p. 2691-2701 11 p.

Research output: Contribution to journalArticle

Azacitidine
National Cancer Institute (U.S.)
Epigenomics
Breast Neoplasms
Triple Negative Breast Neoplasms